Login to Your Account

Investors Dump Nuvelo On Alfimeprase's Phase III Data

By Aaron Lorenzo

Tuesday, December 12, 2006
Bad news for Nuvelo Inc.: Its partnered thrombolytic drug alfimeprase failed two Phase III studies, one in acute peripheral arterial occlusion (PAO) and the other in catheter occlusion (CO). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription